Abdominal Pain
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Adenocarcinoma of pancreas
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Adenomatous Polyposis Coli
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We provide an overview of newly described genes and syndromes associated with predisposition to CRC and polyposis, including: polymerase proofreading-associated polyposis, NTHL1-associated polyposis, mismatch repair gene biallelic inactivation-related adenomatous polyposis (including MSH3- and MLH3-associated polyposes), GREM1-associated mixed polyposis, RNF43-associated serrated polyposis, and RPS20 mutations as a rare cause of hereditary nonpolyposis CRC.
|
30862463 |
2019 |
Adult Medulloblastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We demonstrate that gain of 8q and expression levels of three 8q-mapped candidate genes (EEF1D, RPL30, RPS20) are associated with adverse outcome in medulloblastoma.
|
16968546 |
2006 |
Agnosia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Amaurosis Fugax
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Anxiety
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the Commercial, Medicare, and Medi-Cal populations, patients with AD had a significantly higher overall comorbidity burden (P < 0.0001), an increased risk of asthma and allergic rhinitis (both P < 0.0001), higher HCRU (P < 0.05), and higher mean total per patient costs (Commercial: US$10,461 versus US$7187; Medicare: US$16,914 versus US$13,714; Medi-Cal; US$19,462 versus US$10,408; all P < 0.0001), compared with matched non-AD controls.
|
28707285 |
2017 |
Attention deficit hyperactivity disorder
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Autoimmune Chronic Hepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
With this two-phase approach, we identified three new antigens, RPS20, Alba-like, and dUTPase, as highly AIH-specific biomarkers, with sensitivities of 47.5% (RPS20), 45.5% (Alba-like), and 22.7% (dUTPase).
|
19545157 |
2010 |
Autoimmune hepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
With this two-phase approach, we identified three new antigens, RPS20, Alba-like, and dUTPase, as highly AIH-specific biomarkers, with sensitivities of 47.5% (RPS20), 45.5% (Alba-like), and 22.7% (dUTPase).
|
19545157 |
2010 |
Benign neoplasm of central nervous system
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Carcinogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Finally, the inverse correlation of GNL1 and RPS20 expression in primary colon and gastric cancers with patient survival strengthen their critical importance during tumorigenesis.
|
30061673 |
2018 |
Carcinoma, Basal Cell
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Cardiac diverticulum
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Cardiovascular Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We evaluated two PTGS2 (rs20417, rs689470), and three PTGER2 (rs708494/uS5, rs708495/uS7, and chr14: 50 764 013/uS10) gene polymorphisms among 600 Caucasian male participants of the Physicians' Health Study with incident myocardial infarction (MI) or ischemic stroke and 600 age- and smoking-matched controls who remained free of all reported cardiovascular disease.
|
16879213 |
2006 |
Central Diabetes Insipidus
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Inpatients for whom CDI was the main reason for hospitalization incurred mean costs of US$10,528 and an average LOS of 5.9 days.
|
30690052 |
2019 |
Childhood Medulloblastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We demonstrate that gain of 8q and expression levels of three 8q-mapped candidate genes (EEF1D, RPL30, RPS20) are associated with adverse outcome in medulloblastoma.
|
16968546 |
2006 |
Colon Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic linkage analysis, exome sequencing, tumor studies, and functional investigations of 4 generations of a FCCX family led to the identification of a truncating germline mutation in RPS20, which encodes a component (S20) of the small ribosomal subunit and is a new colon cancer predisposition gene.
|
24941021 |
2014 |
Colonic Neoplasms
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Colorectal cancer, hereditary nonpolyposis, type 1
|
0.300 |
Biomarker
|
disease |
CLINGEN |
Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in an Analysis of Families and Patients-a Systematic Review.
|
27713038 |
2017 |
Colorectal cancer, hereditary nonpolyposis, type 1
|
0.300 |
Biomarker
|
disease |
CLINGEN |
Germline mutation of RPS20, encoding a ribosomal protein, causes predisposition to hereditary nonpolyposis colorectal carcinoma without DNA mismatch repair deficiency.
|
24941021 |
2014 |
Colorectal Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We therefore found published evidence to support the association between variants in NTHL1 and RPS20 with CRC, but not of other recently reported CRC susceptibility variants.
|
27713038 |
2017 |
Colorectal Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We provide an overview of newly described genes and syndromes associated with predisposition to CRC and polyposis, including: polymerase proofreading-associated polyposis, NTHL1-associated polyposis, mismatch repair gene biallelic inactivation-related adenomatous polyposis (including MSH3- and MLH3-associated polyposes), GREM1-associated mixed polyposis, RNF43-associated serrated polyposis, and RPS20 mutations as a rare cause of hereditary nonpolyposis CRC.
|
30862463 |
2019 |
Congenital Abnormality
|
0.010 |
Biomarker
|
group |
BEFREE |
Human cytomegalovirus (HCMV) infection, which is the major cause of congenital defects, encodes multiple glycoproteins (US2, US3, US6, US10 and US11) that interrupt the MHC class I pathway of antigen presentation.
|
15288176 |
2004 |